Navigation Links
Vasogen Announces First Quarter 2009 Results
Date:4/13/2009

pre>

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to consider a sale, merger, acquisition, or other alternatives resulting from our strategic review, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vasogen Announces 2008 Year-End Results
2. Vasogen Announces Sale of Patent Application and Provides Corporate Update
3. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
4. Vasogen Provides Corporate Update
5. Vasogen Announces Third Quarter 2008 Results
6. Vasogen Announces Second Quarter 2008 Results
7. Vasogen Provides Corporate Update
8. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
10. Vasogen Announces Implementation of Strategic Restructuring Plan
11. Vasogen Announces First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... as a result of recent discussions with certain shareholders ... of the Company, after dealing with certain matters including ... meeting of shareholders on March 26, 2015 (the "Meeting") ... election of directors will take place when the Meeting ...
(Date:3/25/2015)... Md. , March 25, 2015 Accelovance, ... named a finalist for "Best Contract Research Organization" at ... the World Vaccine Congress. This is ... a finalist for the award, winning for "Best Contract ... a "Highly Recommended" distinction in 2013. "We,re ...
(Date:3/25/2015)... 25, 2015 Having added two International ... part of 2014, ITRA Global proudly announced recently the ... Tenant Representative Alliance, based in the United States, is ... and occupiers of commercial real estate. , Saltwood ... in Poland that exclusively advises occupiers of office space, ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2International Organization Expands its Global Reach to Warsaw, Poland 2
... Technology (NIST) has issued a new ruler, and even for ... records. Designed to be the most accurate commercially available "meter ... standard for X-ray diffractionboasts uncertainties below a femtometer. That,s 0.000 ... a neutron. The new ruler is in the form ...
... , , , ... a prospective registry showed good safety in a broad population of patients ... Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI). , , ... of major adverse cardiac events (MACE) was 6.7 percent and the rate ...
... SAN DIEGO, Sept. 22 SoluLinK, Inc., a leader ... Catalyst, making conjugation at least 20 times faster than before ... , , Up to now, researchers, conjugation ... poor yields, poor quality and more labor and time consuming ...
Cached Biology Technology:New NIST nano-ruler sets some very small marks 2OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI 3SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100% Yields 2
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
(Date:3/5/2015)... March 5, 2015 In Brazil ... companies already using these solutions and 42 percent planning to ... latter, approximately 25 percent of the companies will be investing ... the majority of companies in the region are currently opting ... hybrid model will command significant attention in the coming years. ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... in their genes" is a common refrain from scientists when ... and beyond. Up until now, research has focused on ... levels of HDL ("good") cholesterol. But researchers at Albert ... of Psychology of Yeshiva University have found that personality ...
... Preventice, Inc. , a developer of mobile health ... it is the latest to join medical device ... payors that are integrating with Qualcomm Life Inc., ... their 2net™ Ecosystem. (Logo: http://photos.prnewswire.com/prnh/20120417/CG89172LOGO ...
... Diego have discovered that a small dose of a commonly ... affects their ability to recruit their nestmates to otherwise good ... this week,s issue of the Journal of Experimental Biology ... bee-pollinated crops and shed light on one of the main ...
Cached Biology News:'Personality genes' may help account for longevity 2Preventice Expands Options for Wireless Patient Monitoring with Qualcomm Life 2Commonly used pesticide turns honey bees into 'picky eaters' 2
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
... to Uridine Phosphorylase 1 ( Abpromise ... Antigen: Synthetic peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK ... corresponding to amino acids 1-99 of Human ... Gene ID: 7378 ...
Request Info...
Syne-1 (N-19)...
Biology Products: